IBDEI3IF ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1242,0)
 ;;=GASTROENTEROLOGY^3^124
 ;;^UTILITY(U,$J,358.4,1243,0)
 ;;=GENITORURINARY^4^124
 ;;^UTILITY(U,$J,358.4,1244,0)
 ;;=MUSCULOSKELETAL^8^124
 ;;^UTILITY(U,$J,358.4,1245,0)
 ;;=NEUROLOGY^9^124
 ;;^UTILITY(U,$J,358.4,1246,0)
 ;;=HEMATOLOGY/ONCOLOGY^5^124
 ;;^UTILITY(U,$J,358.4,1247,0)
 ;;=INFECTIOUS CONTROL^6^124
 ;;^UTILITY(U,$J,358.4,1248,0)
 ;;=SUBSTANCE ABUSE-ALCOHOL^13^124
 ;;^UTILITY(U,$J,358.4,1249,0)
 ;;=SUBSTANCE ABUSE-AMPHETAMINE^14^124
 ;;^UTILITY(U,$J,358.4,1250,0)
 ;;=SUBSTANCE ABUSE-CANNABIS^15^124
 ;;^UTILITY(U,$J,358.4,1251,0)
 ;;=SUBSTANCE ABUSE-COCAINE^16^124
 ;;^UTILITY(U,$J,358.4,1252,0)
 ;;=SUBSTANCE ABUSE-HALLUCINOGEN^17^124
 ;;^UTILITY(U,$J,358.4,1253,0)
 ;;=SUBSTANCE ABUSE-INHALANT^18^124
 ;;^UTILITY(U,$J,358.4,1254,0)
 ;;=SUBSTANCE ABUSE-OPIOID^19^124
 ;;^UTILITY(U,$J,358.4,1255,0)
 ;;=SUBSTANCE ABUSE-PSYCHOACTIVE DRUGS^20^124
 ;;^UTILITY(U,$J,358.4,1256,0)
 ;;=SUBSTANCE ABUSE-SEDATIVE/HYPNOTIC^21^124
 ;;^UTILITY(U,$J,358.4,1257,0)
 ;;=SUBSTANCE ABUSE-TOBACCO^22^124
 ;;^UTILITY(U,$J,358.4,1258,0)
 ;;=BIOPSY^1^125
 ;;^UTILITY(U,$J,358.4,1259,0)
 ;;=CENTRAL VENOUS ACCESS PROCEDURES^2^125
 ;;^UTILITY(U,$J,358.4,1260,0)
 ;;=PERIPHERAL ANGIOPLASTIES^3^125
 ;;^UTILITY(U,$J,358.4,1261,0)
 ;;=PROSTHETIC ANEURYSM REPAIR^4^125
 ;;^UTILITY(U,$J,358.4,1262,0)
 ;;=VASCULAR INJECTION PROCEDURES^5^125
 ;;^UTILITY(U,$J,358.4,1263,0)
 ;;=NEW PATIENT^2^126
 ;;^UTILITY(U,$J,358.4,1264,0)
 ;;=ESTABLISHED PATIENT^1^126
 ;;^UTILITY(U,$J,358.4,1265,0)
 ;;=CONSULTATIONS^3^126
 ;;^UTILITY(U,$J,358.4,1266,0)
 ;;=COMMON VASCULAR DX^1^127
 ;;^UTILITY(U,$J,358.4,1267,0)
 ;;=ABDOMINAL PAIN^2^127
 ;;^UTILITY(U,$J,358.4,1268,0)
 ;;=AFTERCARE POST SURGERY^3^127
 ;;^UTILITY(U,$J,358.4,1269,0)
 ;;=CARDIOVASCULAR^4^127
 ;;^UTILITY(U,$J,358.4,1270,0)
 ;;=GENERAL/SIGNS/SYMPTOMS^5^127
 ;;^UTILITY(U,$J,358.4,1271,0)
 ;;=HEMATOLOGY/ONCOLOGY^6^127
 ;;^UTILITY(U,$J,358.4,1272,0)
 ;;=INFECTIOUS DISEASE^7^127
 ;;^UTILITY(U,$J,358.4,1273,0)
 ;;=METASTATIC CANCER SITES^8^127
 ;;^UTILITY(U,$J,358.4,1274,0)
 ;;=POST-OP COMPLICATIONS^9^127
 ;;^UTILITY(U,$J,358.4,1275,0)
 ;;=RESPIRATORY^10^127
 ;;^UTILITY(U,$J,358.4,1276,0)
 ;;=BLIND REHAB SERVICE CODES^1^128
 ;;^UTILITY(U,$J,358.4,1277,0)
 ;;=REFRACTION^5^128
 ;;^UTILITY(U,$J,358.4,1278,0)
 ;;=GLASSES/CONTACT LENSES^2^128
 ;;^UTILITY(U,$J,358.4,1279,0)
 ;;=VISUAL FIELDS^8^128
 ;;^UTILITY(U,$J,358.4,1280,0)
 ;;=PHOTOGRAPHY^4^128
 ;;^UTILITY(U,$J,358.4,1281,0)
 ;;=LOW VISION^3^128
 ;;^UTILITY(U,$J,358.4,1282,0)
 ;;=SPECIAL PROCEDURES^6^128
 ;;^UTILITY(U,$J,358.4,1283,0)
 ;;=TEAM MEETINGS/COUNSELING^7^128
 ;;^UTILITY(U,$J,358.4,1284,0)
 ;;=ESTABLISHED PATIENT^1^129
 ;;^UTILITY(U,$J,358.4,1285,0)
 ;;=NEW PATIENT^2^129
 ;;^UTILITY(U,$J,358.4,1286,0)
 ;;=CONSULTATION^3^129
 ;;^UTILITY(U,$J,358.4,1287,0)
 ;;=PROLONGED SERVICE^4^129
 ;;^UTILITY(U,$J,358.4,1288,0)
 ;;=CONJUNCTIVA/CORNEA^2^130
 ;;^UTILITY(U,$J,358.4,1289,0)
 ;;=DIABETES^3^130
 ;;^UTILITY(U,$J,358.4,1290,0)
 ;;=GLAUCOMA^4^130
 ;;^UTILITY(U,$J,358.4,1291,0)
 ;;=LENS/VITREOUS^5^130
 ;;^UTILITY(U,$J,358.4,1292,0)
 ;;=LIDS/LASHES^6^130
 ;;^UTILITY(U,$J,358.4,1293,0)
 ;;=MACULA/OPTIC NERVE^7^130
 ;;^UTILITY(U,$J,358.4,1294,0)
 ;;=PUPILS/IRIS^8^130
 ;;^UTILITY(U,$J,358.4,1295,0)
 ;;=RETINA^9^130
 ;;^UTILITY(U,$J,358.4,1296,0)
 ;;=VF HA EOM OTHER^10^130
 ;;^UTILITY(U,$J,358.4,1297,0)
 ;;=VA VF^1^130
 ;;^UTILITY(U,$J,358.4,1298,0)
 ;;=MFH-NON CLINICIAN VISIT ^2^131
 ;;^UTILITY(U,$J,358.4,1299,0)
 ;;=NURSING PROCEDURES^3^131
 ;;^UTILITY(U,$J,358.4,1300,0)
 ;;=SPLINTS^4^131
 ;;^UTILITY(U,$J,358.4,1301,0)
 ;;=MFH-CLINICIAN VISIT ^1^131
